(TSX-V:CPI),(OTC US:NBRFF),(OTCQB:NBRFF), TORONTO, March 19, 2025 (GLOBE NEWSWIRE) — Carlton Precious Inc. (TSX-V: CPI | OTCQB: NBRFF) (“Carlton” or the “Company“) is pleased to report that it has received assay results from recent surface channel sampling program across multiple silver-lead-zinc (Au-Ag-Cu-Pb-Zn) veins at its Esquilache Project in southern Peru (“Esquilache” or the “Project”). Twenty-four channel […]
$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling studies in 2025 Second discovery partnership in obesity initiated BOSTON, March 19, 2025 (GLOBE NEWSWIRE) — Ampersand Biomedicines, a multi-product platform company developing smarter medicines that
(PinkSheets:LUCN),(Pinksheets:TMEF),(PinkSheets:TMEF),(Pinksheets:LUCN), New Symbol Reflects Company's Commitment to Sustainable Innovation Irvine, Ca, March 19, 2025 (GLOBE NEWSWIRE) — Lucent, Inc. (“Lucent” or the “Company”) (Formerly OTC: TMEF) (OTC: LUCN) today announced announced that the stock symbol of the corporation will change to “LUCN” at market opening on March 19, 2025. The new symbol better reflects the
(NASDAQ:BNTC), -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function
NEWTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) — Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced the appointment of Glenn Goddard as Chief Financial Officer. Mr. Goddard is a seasoned biopharma executive with more than 25 years of leadership experience in biotechnology companies,
(NASDAQ:BDTX), The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancer Black Diamond will receive an upfront payment of $70 million
San Francisco, CA, March 19, 2025 (GLOBE NEWSWIRE) — Evinova, a global clinical trial technology company with proven published outcomes for sponsors, sites and patients, announced today an agreement with Quantum Leap Healthcare Collaborative(TM) (QLHC) to incorporate Evinova's remote patient monitoring (RPM) solution into I-SPY 2.2. I-SPY 2.2 is the largest and longest-running 'platform' trial
(TSX:SVI), TORONTO, March 19, 2025 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation“) (SVI-TSX) is pleased to announce that it has received conditional acceptance from the Toronto Stock Exchange (the “TSX“) to conduct a Normal Course Issuer Bid (“NCIB“) to purchase for cancellation, during the 12-month period starting March 21, 2025: (i) up
(TASE:KMDA.TA),(NASDAQ:KMDA), New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D Specialty Plasma Collected will Support the Company's Increasing Demand for Hyper-Immune Plasma, and is Expected to Lower Raw Material Costs Expected Annual Revenue Contribution
(NASDAQ:SMPL),(NASDAQ:SMPL.W), DENVER, March 19, 2025 (GLOBE NEWSWIRE) — The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today announced it will report financial results for the 13 week fiscal second quarter ended March 1, 2025, on Wednesday, April 9,